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Abstract 
The solid-liquid solubility of the thermodynamically stable form I of the drug risperidone has 
been determined by a gravimetric method in nine pure organic solvents in the temperature 
range 278.15–323.15 K. The melting temperature and associated enthalpy of fusion of 
risperidone form I has been determined by differential scanning calorimetry (DSC) to be 
442.38 K and 43.94 kJ mol-1, respectively. The heat capacity of the solid form I and the melt 
have been determined over a range of temperatures by temperature-modulated DSC, and 
extrapolated data has been used to calculate the Gibbs energy, enthalpy and entropy of fusion 
from ambient temperature up to the melting point. The ideal solubility within a Raoult’s law 
framework is obtained from the Gibbs energy of fusion, and the solution activity coefficient 
at equilibrium in the nine solvents quantified. Solutions in all solvents exhibit positive 
deviation from Raoult’s law, with the highest solubility (closest to ideality) in toluene, an 
aprotic apolar solvent. The solubility curves plotted in a van’t Hoff graph show non-linear 
behaviour and are well-approximated by a second order polynomial. 
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1. Introduction 
The solid-liquid solubility of an organic pharmaceutical compound is a very important 
property which affects its entire lifespan, from synthesis through isolation and formulation 
down to its bioavailability within the human body. Having access to accurate solubility data 
in a relevant selection of solvents is crucial for the control and optimisation of different steps 
of the manufacturing process. It is of particular importance in crystallisation processes, where 
knowledge of the solubility is needed in order to be able to control the supersaturation, 
particle size, desired polymorphic form and yield.  
Risperidone, CAS number 106266-06-2, is an atypical benzisoxazole neuroleptic drug mainly 
used to treat schizophrenia, manic states associated with bipolar disorder, and schizoaffective 
disorder. Its main pharmacological activity is the blocking of the serotonin type 2 (5HT2) 
receptor and dopamine type 2 (D2) antagonism [1]. The molecular formula of risperidone is 
C23H27FN4O2 (M.W. 410.485 g mol
-1) and its molecular structure is shown in Fig. 1. There 
are two reported polymorphs with crystal structures available in the Cambridge Structural 
Database (CSD) [2, 3]. However, very limited data is available on the solid-liquid solubility 
of risperidone. 
In this work, we report the solubility over the temperature range 278.15–323.15 K in nine 
pure organic solvents of the stable polymorph of risperidone, sometimes referred to as form 
A but henceforth termed form I in accordance with McCrone’s generally accepted standard 
naming conventions [4]. The melting properties and the heat capacity of the pure compound 
in the solid state and as a melt have been determined. Based on the thermal analysis, the 
thermodynamics of fusion of the solid are investigated, and the ideal solubility is estimated as 
a function of temperature, allowing activity coefficients in the nine solvents to be calculated. 
 
Fig. 1. Molecular structure of risperidone. 
2. Experimental work 
2.1 Materials 
Table 1 lists the chemicals used, together with the source and stated purity. All chemicals 
were used as received without further purification.  
 
 
 
3 
 
Table 1. Source and mass fraction purity of chemicals. 
Compound Source Purity 
Risperidone Janssen Pharmaceuticals, Ireland >0.9995 
Methanol VWR International 0.998 
Ethanol VWR International 0.998 
1-Propanol VWR International 0.998 
2-Propanol VWR International 0.998 
1-Butanol VWR International 0.998 
Acetone VWR International 0.998 
Ethyl acetate VWR International 0.998 
Toluene VWR International 0.998 
Cumene VWR International 0.998 
 
2.2 Solubility 
Solubility was determined using a gravimetric method described previously [5]. Temperature 
was controlled using a Grant S26 water bath equipped with a GR150 control unit (specified 
stability of ±0.005 K) and a Grant C2G cooling unit. A temperature uniformity of ±0.01 K 
was achieved by providing additional agitation to the bath using a submersible pump. A 60-
point submersible magnetic stirring plate (2Mag) provided agitation at 600 rpm. Solutions 
were equilibrated for 24 h at each temperature in 20 ml glass vials (70 x 25 mm), each 
containing a PTFE coated magnetic stirring bar (13 x 3 mm) and sealed with a screw cap with 
a PTFE coated insert. Equilibrium was always approached from below the desired 
temperature point (i.e. via dissolution). After the equilibration period stirring was switched 
off for 1 h to allow excess solids to settle in the vials. A sample of the excess solid material in 
each vial was collected. Samples of the clear solution (approx. 4 ml) were extracted in 
triplicate using pre-heated syringes and filtered through 0.2 μm solvent-compatible (PTFE or 
Nylon) filters into pre-weighed glass vials (50 x 25 mm). The filtered solutions were then 
immediately capped and weighed. The caps were then removed and stored, allowing the 
solvent to evaporate at room temperature for a period of at least 3 days in a ventilated fume 
hood. When vials were visibly solvent-free they were placed in an oven at 323 K for 8 h to 
ensure dryness before being placed in a desiccator overnight to return to ambient temperature. 
The dry vials were then weighed together with the caps to determine the amount of 
risperidone dissolved in the solution. All weights were determined with an Ohaus Explorer 
balance accurate to ±0.0001 g. In each of the nine solvents listed in section 2.1, solubility was 
measured in the temperature range 278.15–323.15 K with steps of 5 K. X-ray powder 
diffraction (XRPD, Philips PANalytical X’Pert MPD Pro with a PW3064 sample spinner) 
was used to analyse the sampled excess solid material. Scans in the 2θ-range 5–35 ° allowed 
identification of the polymorph by comparison with the theoretical patterns generated from 
the structures published in the CSD.  
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2.3 Thermal analysis 
The melting temperature, Tm, and the associated enthalpy of fusion, ΔfusH, of risperidone 
form I were determined by differential scanning calorimetry (DSC) using a PerkinElmer 
Pyris 1, in six repeat runs using a constant heating rate of 1 K min-1 from 293–453 K. 
Samples were prepared in hermetically sealed aluminium pans with the furnace purged with 
nitrogen gas at a rate of 50 ml min-1. 
Heat capacity measurements were conducted using a TA Instruments MDSC 2920 operated 
in modulated mode using non-hermetic aluminium sample pans. A modulation period of 100 
s and amplitude of 1 K were used, with an underlying constant heating rate of 3 K min-1. Each 
powder sample (4–9 mg) was distributed evenly in the pan and covered with a lid without 
crimping, and the furnace was purged with nitrogen gas at a rate of 50 ml min-1. The heat 
capacity of the solid was measured by heating the material once to just below its melting 
point. The heat capacity of the melt was obtained in dual scans of each sample, by heating the 
solid material past the melting point to 458 K, then cooling the melt to 428 K followed by 
heating the melt to 458 K (first scan), then cooling the melt to 423 K followed by heating the 
melt to 453 K (second scan), discarding scans where the melt recrystallized during cooling. 
Calibration of both calorimeters was carried out according to standard procedure against the 
melting properties of indium. Heat capacity calibration was made using sapphire and a linear 
calibration correction function based on three repeat scans from 273–473 K. Differences in 
mass between sample pan and reference pan were within ±0.10 mg.  
Thermogravimetric analysis (TGA) was carried out using a TA Instruments SDT Q600, 
conducted under both air and nitrogen gas atmosphere, respectively, using a flow rate of 100 
ml min-1. Samples were prepared in open alumina pans and heated at a rate of 10 K min-1 
from 298–773 K. 
3. Results 
3.1 Thermal analysis 
A representative DSC thermogram of the melting of form I is shown in Fig. 2a. The average 
values over six DSC scans of the melting temperature (Tm) and the enthalpy of fusion at the 
melting temperature (ΔfusH) of form I are given in Table 2. The value of Tm determined in 
this work as the mean extrapolated onset temperature (442.4 K) is slightly less than the value 
reported by Silva et al. [6] (443.6 K), and slightly higher than those reported by Germann et 
al. [1] (441.8 K) and Shah et al. [7] (439.9 K), although it should be noted that these studies 
all used risperidone of unspecified or lower purity, higher heating rates (5–10 K min-1), and 
give no estimate on the confidence of their data. The value of the melting enthalpy 
determined here (43.94 kJ mol-1) is slightly lower than the value reported by Silva et al. [6] 
(45.28 kJ mol-1). No evidence of solid phase transformation prior to melting was observed.  
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Table 2. Melting properties of risperidone form I with 95% confidence interval for the mean. 
Tm a/ K 442.38 ± 0.26 
ΔfusH b / kJ mol-1 43.94 ± 0.15 
ΔfusH / J g-1 107.05 ± 0.35 
ΔfusS / J K-1 mol-1  99.33 ± 0.34 
a Standard uncertainty u(Tm) = 0.10 K.  
b Standard uncertainty u(ΔfusH) = 0.058 kJ mol-1. 
 
Examination of the DSC pan contents after heating to 10 K past Tm followed by 
recrystallisation during cooling to room temperature indicates a colour change from white to 
yellow, which could suggest partial decomposition. This was investigated using TGA, and 
the results are shown in Fig. 2 b. Detectable mass loss began to occur after approx. 490 K in 
air, with 0.01% mass loss reached at 492 K. Under nitrogen atmosphere, mass loss was not 
detected until approx. 500 K, with 0.01% mass loss attained at 504 K. The absence of 
volatilisation until 490 K lends confidence to the results of the calorimetric analyses, which 
were conducted well below the lowest temperature of detectable sublimation and/or 
decomposition. 
 
Fig. 2. a) DSC thermogram of risperidone form I heated at a rate of 1 K min-1 (red solid line), 
and b) TGA analysis of pure risperidone form I heated at a rate of 10 K min-1 under air (green 
dashed line) and nitrogen (blue solid line). 
Fig. 3 shows the heat capacity of solid form I, determined in the temperature interval 270–
410 K and averaged over four scans, and that of the melt, determined in the temperature 
interval 430–453 K, well below the onset temperature of decomposition as indicated by TGA, 
from 430–435 K as the average of four scans and from 435–453 K as the average of eight 
scans, with each sample scanned in duplicate. Both data sets are well described by a linear 
model over the experimental temperature interval, Eq. (1) (units of J K-1 mol-1). Regression 
coefficients and scan details are given in Table 3, and experimental heat capacity data is 
provided as supplementary data (table A.1). 
21 kTkC p            (1) 
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Table 3. Heat capacity coefficients of Eq. (1) for form I and the melt, together with goodness 
of fit. 
Phase Scans T-range 
/ K 
k1 
/ J K-2 mol-1  
k2 
/ J K-1 mol-1  
R2 
Solid (form I) 4 270–410 1.3020 113.8 0.999 
Melt 8 430–453 0.7806 502.6 0.981 
 
 
Fig. 3. Heat capacity of form I (dark blue solid line) and the melt (dark green solid line) with 
lighter wrapping lines showing 90% confidence limits, dotted lines indicating extrapolation 
lines, and purple solid line shows the heat capacity difference between the melt and the solid 
obtained by linear extrapolation. 
3.2 Solubility 
The solubility of risperidone form I between 278.15–323.15 K in the nine evaluated solvents 
is given in Table 4 as mole fractions, and shown in Fig. 4 as g risperidone per kg solvent. 
Values are averages over three samples from each solution. The main reason for the chosen 
upper limit in temperature is that data was chiefly intended to support a separate study of 
primary nucleation conducted in this temperature region (to be published separately). In 
addition, it was observed that solutions equilibrated for extended periods at higher 
temperatures would gradually take on a yellow hue, suggesting degradation. No colour 
changes were observed in the chosen temperature range in any of the investigated solvents. 
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Fig. 4. The solubility of risperidone form I expressed as g kg-1 solvent in nine pure solvents, 
shown together with fits of Eq. (2). 
Table 4. Mole fraction solubility (xeq) of risperidone form I with associated standard 
uncertainty u(x) calculated as the standard deviation of the mean.  
 Methanol Ethanol 1-Propanol 2-Propanol 1-Butanol 
T a / K  103 xeq 103 u(x) 103 xeq 103 u(x) 103 xeq 103 u(x) 103 xeq 103 u(x) 103 xeq 103 u(x) 
278.15 2.02 0.072 0.96 0.019 1.39 0.011 0.36 0.018 1.52 0.047 
283.15 2.30 0.011 1.08 0.016 1.55 0.018 0.46 0.028 1.73 0.064 
288.15 2.72 0.025 1.31 0.037 1.97 0.046 0.6 b 0.12 2.2 0.15 
293.15 3.285 0.0065 1.53 0.020 2.378 0.0068 0.70 0.026 2.63 0.050 
298.15 3.96 0.015 2.009 0.0064 3.049 0.0040 1.03 0.022 3.47 b 0.011 
303.15 4.87 0.012 2.48 0.011 3.810 0.0075 1.36 0.024 4.427 0.0070 
308.15 6.15 0.021 3.30 0.052 5.17 0.034 2.03 b 0.023 5.93 0.081 
313.15 7.70 0.014 4.151 0.0010 6.51 0.032 2.53 0.044 7.53 0.019 
318.15 9.90 0.030 5.10 0.036 8.39 0.028 3.2 0.10 9.63 0.015 
323.15 12.83 0.040 6.770 0.0081 10.89 0.048 4.475 0.0054 12.41 0.025 
 Acetone Ethyl Acetate Toluene Cumene 
T a / K  103 xeq 103 u(x) 103 xeq 103 u(x) 103 xeq 103 u(x) 103 xeq 103 u(x) 
278.15 0.85 0.026 1.16 0.032 3.8 0.19 1.22 0.065 
283.15 0.95 0.034 1.28 0.058 4.18 0.020 1.47 0.026 
288.15 1.27 0.034 1.674 b 0.0026 5.210 0.0079 2.07 0.028 
293.15 1.43 0.011 1.85 0.047 5.59 0.065 2.19 0.023 
298.15 1.754 0.0075 2.16 0.024 6.67 0.051 2.60 0.012 
303.15 2.19 0.013 2.628 0.0071 8.0 0.13 3.09 0.030 
308.15 2.84 0.031 3.31 0.056 9.98 0.082 3.76 0.028 
313.15 3.36 0.020 3.974 0.0061 11.73 0.029 4.81 0.042 
318.15 4.17 0.060 4.85 0.063 14.0 0.13 5.52 0.051 
323.15 5.07 0.012 5.80 0.027 16.68 0.044 6.6 0.11 
a Standard uncertainty u(T) = 0.032 K.  b Based on two samples. 
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The mole fraction solubility data in each solvent was correlated by Eq. (2): 
CBTATx   12eqln         (2) 
where T is the temperature in K and A, B and C are regression coefficients valid within the 
temperature range 278–323 K. The coefficients of Eq. (2) obtained for each solvent by least 
squares fitting to the data in Table 4 are displayed in Table 5 together with coefficients of 
determination.  
 
Fig. 5. XRPD patterns of excess solids from solubility measurements at 293 K in nine pure 
solvents, shown together with predicted patterns of forms I and II. 
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Examples of XRPD patterns of the excess solids in the vials of the solubility experiments are 
presented in Fig. 5. In all solutions, the solid material was verified to be form I. All 
experimental peaks match those in the theoretical pattern generated from the known structure 
of risperidone form I [2] (refcode WASTEP). The theoretical pattern of form II [3] (refcode 
WASTEP01) contains a dominant peak at 21.78 ° and a distinctive region around 17–18 ° 
distinguishing it from form I, both of which are completely absent from all XRPD patterns 
collected.  
Table 5. Coefficients of Eq. (2) for risperidone form I, valid between 278–323 K, together 
with coefficients of determination.  
Solvent 10-6 A 
/ K2 
-10-4 B 
/ K 
C R2 
Methanol 3.438 2.669 45.302 0.999 
Ethanol 3.311 2.612 44.151 0.998 
1-Propanol 3.234 2.584 44.500 0.999 
2-Propanol 2.871 2.434 42.461 0.996 
1-Butanol 2.969 2.418 42.021 0.999 
Acetone 1.749 1.534 25.452 0.997 
Ethyl Acetate 1.985 1.654 27.036 0.997 
Toluene 2.106 1.709 28.647 0.997 
Cumene 0.699 0.799 13.027 0.993 
 
4. Analysis and discussion 
The mole fraction solubility of a solid compound in a solvent at a temperature T is given by 
the activity of the solute in the saturated solution, aeq – which is equal to that of the pure solid 
phase, as – and the activity coefficient at that temperature and concentration, γeq: 
eq
s
eq lnlnln  ax          (3) 
In the customary Raoult’s law definition, the activity of the solid is defined in relation to the 
pure supercooled melt at the same temperature, so that a solution is denoted as ideal when the 
activity coefficient equals unity. Within this definition, the activity of the solid is related to 
the Gibbs energy of fusion, according to Eq’s (4-7) [8, 9]: 
STHG fusfusfus          (4) 
  
T
T
pdTCTHH
m
mfusfus        (5) 
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If the melting temperature and the associated enthalpy of melting are known, and the heat 
capacity difference between the solid and the supercooled liquid can be estimated with 
reasonable confidence, the Gibbs energy of fusion and its enthalpic and entropic components, 
and thence the activity of the pure solid, can be computed as functions of temperature.  
Extrapolating the linear regression models for the heat capacities of form I and the melt, Eq. 
(1), and subtracting the solid from the liquid gives a linearly decaying function for the heat 
capacity difference with increasing T, Eq. (8), with the coefficients q = 158.09 J K-1 mol-1 and 
r = 0.5214 J K-2 mol-1. The extrapolated function is shown in Fig. 3. At Tm, the heat capacity 
difference is equal to q, viz. 158.1 J K-1 mol-1, increasing to 243.7 J K-1 mol-1 at 278 K. 
 TTrqC p  m          (8) 
In Fig. 6, the resulting Gibbs energy of fusion of form I is shown together with its component 
terms. The enthalpy of fusion at room temperature is only about half the value at Tm, showing 
the importance of the heat capacity term in Eq. (5). However, because of enthalpy-entropy 
compensation, ΔfusG only changes by 10 kJ mol-1 from ambient temperature to the melting 
point. 
 
Fig. 6. ΔfusG (red solid line), ΔfusH (blue dashed line) and TΔfusS (green dotted line) of form I 
vs. absolute temperature for risperidone form I estimated using calorimetric melting data and 
heat capacities extrapolated using Eq. (8). 
For an ideal solution, ln γeq equals zero and the solubility equals the activity of the pure solid. 
It has been suggested [10] that, for the purpose of estimating the activity of the solid, ΔCp 
could be approximated by the entropy change upon melting. In the case of risperidone, ΔfusS 
(Tm) as calculated from experimental melting data is 99 J K-1 mol-1, which is quite far below 
the corresponding heat capacity value obtained experimentally and clearly would lead to an 
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underestimation of the influence of ΔCp on the thermodynamics of fusion and the activity of 
the solid.  
In Fig. 7, the activity of solid risperidone, calculated using Eq. (7), is shown as a solid black 
line. Fig. 7 also shows the solubility of risperidone in five representative solvents as ln xeq vs. 
T-1 with lines representing fits of Eq. (2). The curves of the remaining four solvents behave in 
a similar way, and are located within the boundary of the five that are shown, but are omitted 
for clarity.  
 
Fig. 7. ln xeq of form I in five pure solvents plotted against T
-1, shown together with fits of Eq. 
(2). Also shown is the ideal solubility calculated using Eq. (7) together with calorimetric data. 
The solubility curves trend towards the ideal solubility with increasing temperature, as they 
are expected to. In most reported solubility data van’t Hoff plots are shown as straight lines. 
However, as given by Eq. (7) van’t Hoff plots are inherently non-linear, even for ideal 
solutions, and this is indeed the general appearance of the curves in Fig. 7, with the possible 
exception of cumene. A number of regression equations have been proposed for temperature 
correlation of solubility data, many of which were evaluated by Nordström and Rasmuson 
[11]. For risperidone, all of these provide good fits to the experimental solubility data in 
terms of average coefficients of determination, which exceeds 0.97 for all models including a 
linear equation in T-1. However, Fig. 8 clearly shows that a plot of the average residuals in ln 
xeq vs. T are not randomly distributed, which reveals a systematic deviation between the 
straight line and the experimental data, whereas the residuals are much better distributed for 
the second-order polynomial given by Eq. (2).  
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Fig. 8. Average residuals in ln xeq over 9 solvents at different temperatures obtained using a 
linear regression model (hollow bars) and Eq. 2 (filled bars). 
At room temperature the mole fraction solubility decreases in the order: toluene > methanol > 
1 butanol > 1-propanol > cumene > ethyl acetate > ethanol > acetone > 2-propanol. In mole 
fraction terms, the solubility of risperidone form I is quite low in all the solvent systems 
evaluated in this study, with the highest value measured being 0.038 in toluene at 323 K. 
Comparison with the ideal solubility shows that an important reason for the low mole fraction 
solubility is the low activity of the solid phase, which in turn is related to the fact that the 
experimental temperature range is more than 100 K below Tm. However, it should be noted 
that the molecular mass of risperidone is considerably higher than those of the evaluated 
solvents, and consequently the solubility on mass basis, shown in Fig. 4, is fairly reasonable.  
Fig. 9 shows the activity coefficient in all nine solvents as a function of T, obtained by 
combining Eq. (3) and Eq. (7) and inserting experimental solubility and calorimetric data. In 
all the solvents at all temperatures the activity coefficient is clearly above unity, reflecting a 
considerable positive deviation from Raoult’s law. At 278 K, the activity coefficients range 
from 4 (in toluene) to 42 (in 2-propanol). The activity coefficient in all solvents decrease 
monotonically and approach unity with increasing T, as the solution approaches ideality at 
Tm.  
 
Fig. 9. γeq of form I in nine pure solvents plotted against T, shown together with fits based on 
Eq. (2), Eq. (3) and Eq. (7). 
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Fig. 10 shows the electrostatic potential, calculated at the HF/6-311+G(d) level of theory 
using Gaussian 03w, mapped onto an electron density isosurface surrounding a risperidone 
molecule with the geometry corresponding to the form I crystal structure. The hydrocarbon 
parts of the various ring structures (benzyl, piperidine, pyrimidine) provide significant 
nonpolar regions, while the presence of oxygen, nitrogen, and fluorine creates electronegative 
areas suitable for hydrogen bond acceptance, most prominent at the carbonyl oxygen. 
However, notably, risperidone has no significant hydrogen bond donation capability. No 
simple correlation was found between the solubility and various solvent properties relating to 
polarity, e.g. dielectric constant or Reichardt’s polarity parameter [12]. However, the process 
of solvation depends in a complex way on a multitude of other molecular properties of the 
solvent and the solute, such as the relative sizes of solute and solvent molecules, their 
polarisability, and their mutual ability to form strong and efficient interacting aggregates. 
This complexity needs to be considered when attempting to rationalize the differences in 
solubility between the investigated solvents, and the uniformly positive activity coefficients, 
which show that none of the evaluated solvents is capable of forming favourable interactions 
with the entire large, chemically diverse risperidone molecule. Notably, the two solvents with 
the highest mole fraction solubility represent antipodes on a polarity scale. While toluene, 
almost the least polar solvent evaluated, should be capable of adequate solvation of the 
hydrophobic and aromatic parts of the solute molecule, methanol, on the other hand, the most 
polar solvent investigated, should be capable of forming electrostatic interaction with the 
polar parts of the risperidone molecule, primarily through hydrogen bond donation. In order 
to further investigate the effect of nonpolar interactions, the solubility in n-hexane was 
measured at 303.15 K. The resulting value is very low, 0.44 g per kg solvent, corresponding 
to a mole fraction of 0.000092; an order of magnitude below the value in 2-propanol. The 
dramatic decrease in solubility between the apolar aromatic toluene, via cumene with a 
considerable aliphatic component, to the purely aliphatic hexane, points to the importance of 
the aromatic ring in forming interactions with the risperidone molecule.  
 
Fig. 10. HF/6-311+G(d) electrostatic potential mapped onto an electron density isosurface of 
risperidone molecule, with red indicating negative and blue positive charge. 
The possibility to extrapolate solubility data outside the experimental interval with sufficient 
confidence has important potential applications, e.g. for estimating transition temperatures for 
enantiotropic polymorphs, or for estimation of melting properties. Such extrapolations are 
frequently done on the basis of assuming linear van’t Hoff plots [13-16]. It has been shown 
[11] that a linear model will generally lead to poor accuracy, but with a proper choice of 
model extrapolation of van’t Hoff curves to ln xeq = 0 can produce a reasonable estimate of 
the melting properties of the pure solute. At ln xeq = 0 the intersection of the extrapolated 
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van’t Hoff curve with the x-axis (Fig. 7) yields an estimate of the melting temperature. The 
inclination of a van’t Hoff curve at a given temperature gives the van’t Hoff enthalpy of 
solution, Eq. (8), which at Tm is equal to the enthalpy of melting. 
eq
vH
sol
)/1(
ln









T
x
RH         (8) 
For risperidone form I, extrapolation of solubility data using a linear equation in T-1 results in 
unanimously overestimated values of the melting temperatures, by 119 K on average. This is 
as expected, given the non-linear shapes of the curves in the van’t Hoff plot, Fig. 7, and in 
agreement with results reported for other pharmaceutical molecules in organic solvents [11]. 
Extrapolation of the second-order polynomial given by Eq. (2) using the parameters in Table 
5 leads to melting temperatures ranging from 397.7 K to 507.6 K, with an average over all 9 
solvents of 426.5 K, which is an underestimation by 16 K compared to the experimental 
value (442.4 K). Data in acetone and ethyl acetate result in reasonably accurate estimates of 
Tm, with errors of 5.4 K and 7.6 K, respectively. Data in all alcohols lead to large 
underestimations of Tm, whereas extrapolation of cumene data results in a large 
overestimation. As regards the melting enthalpy, extrapolation of Eq. (2) in all solvents, with 
the exception of cumene, result in clear overestimations of the melting enthalpy, by on 
average 26.3 kJ mol-1, compared to the experimental value (43.9 kJ mol-1). It is clear that data 
covering a wider temperature range, as well as a better functional form for the solubility 
temperature dependence, which distinguishes the contributions to solubility from the solid 
state activity from that of the activity coefficient at equilibrium, is needed for accurate and 
consistent extrapolations.  
5. Conclusions 
The melting point of risperidone form I is determined to be 442.4 K, and the associated 
enthalpy of fusion is 43.9 kJ mol-1. The heat capacity of form I increases linearly from 471 to 
647 J K-1 mol-1 over the temperature interval 270–410 K, and the heat capacity of the pure 
melt increases linearly from 839 to 857 J K-1 mol-1 over the interval 430–453 K. The 
extrapolated heat capacity difference between the melt and the solid amounts to 158.1 J K-1 
mol-1 at the melting point and this difference is shown to increase linearly with decreasing 
temperature. The Gibbs energy of fusion and its enthalpic and entropic components is 
determined by extrapolation of calorimetric data from the melting point, and ΔfusG is 
estimated to be 9.4 kJ mol-1 at 298 K, with ΔfusH at 298 K estimated to have decreased to 15.7 
kJ mol-1 from the value at the melting point. 
The mole fraction solubility of risperidone at ambient temperature decreases in the order: 
toluene > methanol > 1-butanol > 1-propanol > cumene > ethyl acetate > ethanol > acetone > 
2-propanol. Solutions of risperidone in all evaluated solvents show positive deviation from 
Raoult’s law, with activity coefficients at 278 K in the range 4–42, decreasing monotonically 
towards unity at the melting point. It is shown that the majority of solubility curves exhibit 
non-linear behaviour in a van’t Hoff graph, but are well approximated by second order 
polynomials in T-1.  
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Nomenclature 
A Solubility regression coefficient / K2 
B Solubility regression coefficient / K 
C Solubility regression coefficient 
C Concentration  / g kg-1 (pure solvent basis) 
Cp Heat capacity / J mol
-1 K-1 
ΔCp Heat capacity difference (melt – solid) / J mol-1 K-1 
k1 Heat capacity regression coefficient / J mol
-1 K-2 
k2 Heat capacity regression coefficient / J mol
-1 K-1 
q Heat capacity difference regression coefficient / J mol-1 K-1  
r Heat capacity difference regression coefficient / J mol-1 K-2  
R Gas constant / J mol-1 K-1 
T Temperature / K 
ΔfusH Enthalpy of fusion / J mol-1  or  / J g-1 
ΔfusS Entropy of fusion / J mol-1 K-1 
ΔfusG Gibbs energy of fusion / J mol-1 
ΔvHsolH van’t Hoff (apparent) enthalpy of solution / J mol-1 
x Mole fraction 
γ Activity coefficient 
Scripts 
eq Equilibrium 
m Melting 
 
Appendix A. Supplementary data 
The following are the supplementary data to this article: 
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